Vir Biotechnology, Inc. (VIR)
NASDAQ
Closed
Oct 9, 2026
Day's Range
11.0452 wk Range
4.82Overview - VIR - Vir Biotechnology, Inc.
Key Statistics
Valuation
Enterprise Value
1.37B
P/E (Trailing)
‪-3.37‬
P/E (Forward)
‪-4.24‬
PEG Ratio
‪0.02‬
Price / Sales (TTM)
‪5.88‬
Price / Book
‪2.09‬
EV / EBITDA
‪-5.13‬
Profitability
Gross Margin
‪100.00%‬
Profit Margin
‪-83.00%‬
Operating Margin
‪30.74%‬
Return on Assets
‪-14.51%‬
Return on Equity
‪-26.08%‬
Ownership
Shares Outstanding
169.18M
Float
129.80M
Short % of Shares Outstanding
‪11.76%‬
Held by Insiders
‪6.57%‬
Held by Institutions
‪84.22%‬
Price stats
Beta
‪1.62‬
50-Day Avg
‪9.95‬
200-Day Avg
‪8.89‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
10 analysts
Average price target
‪$ 21.00‬Shariah Compliance
Report Date: Feb 17, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - VIR - Vir Biotechnology, Inc.
Peers - VIR - Vir Biotechnology, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- VIRNASDAQVir Biotechnology, Inc.1.80BMarket Cap+47.19%52-week change-3.37P/E (Trailing)‪-83.00%‬Profit Margin
- ARGXNASDAQArgenx SE57.50BMarket Cap+14.28%52-week change34.96P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.29.40BMarket Cap-105.72%52-week change38.35P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share24.34BMarket Cap-8.52%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S14.99BMarket Cap+7.48%52-week change17.72P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.13.14BMarket Cap+18.80%52-week change-17.80P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.11.06BMarket Cap+2.75%52-week change154.54P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - VIR - Vir Biotechnology, Inc.
About
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for serious infectious diseases and cancer. The company centers its work on immune-based approaches, including antibody therapeutics and T cell-engaging technologies, to address conditions with…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
